02162.HK
Keymed Biosciences Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 79.75
−0.99%Sep 2, 2026, 13:08 UTC
Kangnuo-B signed an exclusive licensing agreement with Aeira Pte. Ltd. for the registration and commercialization of its self-developed Stapokibart injection (Kangyueda) in 18 countries and regions in Southeast Asia and Central Asia.
Source:Sep 1, 2026, 03:03 UTC
KeyBanc Capital Markets raised its price target on Keysight Technologies to $210 from $195 and maintained an Overweight rating, citing strong demand for AI-related testing solutions.
Source:Aug 31, 2026, 23:17 UTC
China's 2026 National Essential Medicines List took effect on September 1, adding 116 new drugs including four domestic Class 1 innovative drugs and Novo Nordisk's semaglutide.
Aug 20, 2026, 01:34 UTC
KeyMed Biosciences reported interim results for the six months ended June 2026, with revenue of RMB 617 million, up 24% year-on-year, and a net profit of RMB 1.218 billion, turning around from a loss of RMB 78.79 million in the same period last year.
Source:Jul 23, 2026, 04:27 UTC
China's National Medical Products Administration (NMPA) Drug Evaluation Center included CM512 (TSLP/IL-13 bispecific antibody) of Kangnuoya-B (02162) into the Breakthrough Therapy Designation list for treating chronic rhinosinusitis with nasal polyps (CRSwNP).